355 related articles for article (PubMed ID: 15148249)
1. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.
Niikura K; Takano M; Sawada M
Br J Pharmacol; 2004 Jun; 142(3):558-66. PubMed ID: 15148249
[TBL] [Abstract][Full Text] [Related]
2. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
Niikura K; Takeshita N; Takano M
J Bone Miner Res; 2005 Sep; 20(9):1579-88. PubMed ID: 16059630
[TBL] [Abstract][Full Text] [Related]
3. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
Nyman JK; Väänänen HK
Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
[TBL] [Abstract][Full Text] [Related]
4. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
David P; Nguyen H; Barbier A; Baron R
J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
[TBL] [Abstract][Full Text] [Related]
5. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
Qin A; Cheng TS; Pavlos NJ; Lin Z; Dai KR; Zheng MH
Int J Biochem Cell Biol; 2012 Sep; 44(9):1422-35. PubMed ID: 22652318
[TBL] [Abstract][Full Text] [Related]
6. FR177995, a novel vacuolar ATPase inhibitor, exerts not only an inhibitory effect on bone destruction but also anti-immunoinflammatory effects in adjuvant-induced arthritic rats.
Niikura K; Nakajima S; Takano M; Yamazaki H
Bone; 2007 Apr; 40(4):888-94. PubMed ID: 17157574
[TBL] [Abstract][Full Text] [Related]
7. Specific biological functions of vacuolar-type H(+)-ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts.
Sahara T; Itoh K; Debari K; Sasaki T
Anat Rec A Discov Mol Cell Evol Biol; 2003 Feb; 270(2):152-61. PubMed ID: 12524690
[TBL] [Abstract][Full Text] [Related]
8. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.
Sørensen MG; Henriksen K; Neutzsky-Wulff AV; Dziegiel MH; Karsdal MA
J Bone Miner Res; 2007 Oct; 22(10):1640-8. PubMed ID: 17576165
[TBL] [Abstract][Full Text] [Related]
9. Vacuolar ATPase as a drug discovery target.
Niikura K
Drug News Perspect; 2006 Apr; 19(3):139-44. PubMed ID: 16804565
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of osteoclast vacuolar H(+)-ATPase.
Farina C; Gagliardi S
Curr Pharm Des; 2002; 8(23):2033-48. PubMed ID: 12171517
[TBL] [Abstract][Full Text] [Related]
11. 5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity.
Gagliardi S; Nadler G; Consolandi E; Parini C; Morvan M; Legave MN; Belfiore P; Zocchetti A; Clarke GD; James I; Nambi P; Gowen M; Farina C
J Med Chem; 1998 May; 41(10):1568-73. PubMed ID: 9572882
[TBL] [Abstract][Full Text] [Related]
12. Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.
Xu J; Cheng T; Feng HT; Pavlos NJ; Zheng MH
Histol Histopathol; 2007 Apr; 22(4):443-54. PubMed ID: 17290355
[TBL] [Abstract][Full Text] [Related]
13. Proton pumping V-ATPase inhibitor bafilomycin A1 affects Rab7 lysosomal localization and abolishes anterograde trafficking of osteoclast secretory lysosomes.
Matsumoto N; Nakanishi-Matsui M
Biochem Biophys Res Commun; 2019 Mar; 510(3):421-426. PubMed ID: 30717974
[TBL] [Abstract][Full Text] [Related]
14. Characterization and cellular distribution of the osteoclast ruffled membrane vacuolar H+-ATPase B-subunit using isoform-specific antibodies.
Mattsson JP; Skyman C; Palokangas H; Väänänen KH; Keeling DJ
J Bone Miner Res; 1997 May; 12(5):753-60. PubMed ID: 9144341
[TBL] [Abstract][Full Text] [Related]
15. Iejimalides show anti-osteoclast activity via V-ATPase inhibition.
Kazami S; Muroi M; Kawatani M; Kubota T; Usui T; Kobayashi J; Osada H
Biosci Biotechnol Biochem; 2006 Jun; 70(6):1364-70. PubMed ID: 16794315
[TBL] [Abstract][Full Text] [Related]
16. The R740S mutation in the V-ATPase a3 subunit increases lysosomal pH, impairs NFATc1 translocation, and decreases in vitro osteoclastogenesis.
Voronov I; Ochotny N; Jaumouillé V; Owen C; Manolson MF; Aubin JE
J Bone Miner Res; 2013 Jan; 28(1):108-18. PubMed ID: 22865292
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of bafilomycin A1 derivatives as inhibitors of vacuolar H+-ATPase.
Gagliardi S; Gatti PA; Belfiore P; Zocchetti A; Clarke GD; Farina C
J Med Chem; 1998 May; 41(11):1883-93. PubMed ID: 9599238
[TBL] [Abstract][Full Text] [Related]
18. [3H]Bafilomycin as a probe for the transmembrane proton channel of the osteoclast vacuolar H(+)-ATPase.
Mattsson JP; Keeling DJ
Biochim Biophys Acta; 1996 Apr; 1280(1):98-106. PubMed ID: 8634321
[TBL] [Abstract][Full Text] [Related]
19. Novel bone antiresorptive agents that selectively inhibit the osteoclast V-H+-ATPase.
Farina C; Gagliardi S; Nadler G; Morvan M; Parini C; Belfiore P; Visentin L; Gowen M
Farmaco; 2001; 56(1-2):113-6. PubMed ID: 11347950
[TBL] [Abstract][Full Text] [Related]
20. The a3 isoform vacuolar type H⁺-ATPase promotes distant metastasis in the mouse B16 melanoma cells.
Nishisho T; Hata K; Nakanishi M; Morita Y; Sun-Wada GH; Wada Y; Yasui N; Yoneda T
Mol Cancer Res; 2011 Jul; 9(7):845-55. PubMed ID: 21669964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
